TY - JOUR T1 - Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfected patients with compensated cirrhosis JF - Clin Infect Dis Y1 - 2013 A1 - Mira, J.A. A1 - Rivero-Juárez, A. A1 - Lopez-Cortes, L.F. A1 - Giron-Gonzalez, J.A. A1 - Tellez, F. A1 - Santos-Gil, I.D. A1 - Macias, J. A1 - Merino, D. A1 - Marquez, M. A1 - Rios-Villegas, M.J. A1 - Gea, I. A1 - Merchante, N. A1 - Rivero, A. A1 - Torres-Cornejo, A. A1 - Pineda, J.A. KW - Cohort Studies KW - complications KW - Death KW - HCV KW - hepatitis KW - Hepatitis C KW - hepatitis C virus KW - Human KW - Incidence KW - interferon KW - Liver KW - methods KW - Mortality KW - Patients KW - pegylated KW - pegylated interferon KW - Ribavirin KW - sustained virologic response KW - SVR KW - therapy KW - Time VL - 56 SP - 1646-1653 IS - 11 ER -